458
H. Jin
184. Wang TH, Chao A, Tsai CL, Chang CL, Chen SH, Lee YS, Chen JK, Lin YJ, Chang PY, Wang
CJ, Chao AS, Chang SD, Chang TC, Lai CH, Wang HS (2010) Stress-induced phosphoprotein
1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. Mol
Cell Proteomics 9(9):1873–1884. https://doi.org/10.1074/mcp.M110.000802
185. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM (2012)
Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical
infection to cancer. Int J Cancer 131(10):2349–2359. https://doi.org/10.1002/ijc.27485
186. Jeon S, Lambert PF (1995) Integration of human papillomavirus type 16 DNA into the
human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical
carcinogenesis. Proc Natl Acad Sci U S A 92(5):1654–1658. https://doi.org/10.1073/pnas.92.
5.1654
187. Leija-Montoya AG, Benítez-Hess ML, Toscano-Garibay JD, Alvarez-Salas LM (2014) Characterization of an RNA aptamer against HPV-16 L1 virus-like particles. Nucl Acid Ther
24(5):344–355. https://doi.org/10.1089/nat.2013.0469
188. Nicol C, Bunka DH, Blair GE, Stonehouse NJ (2011) Effects of single nucleotide changes
on the binding and activity of RNA aptamers to human papillomavirus 16 E7 oncoprotein.
Biochem Biophys Res Commun 405(3):417–421. https://doi.org/10.1016/j.bbrc.2011.01.044
189. Belyaeva TA, Nicol C, Cesur O, Travé G, Blair GE, Stonehouse NJ (2014) An RNA aptamer
targets the PDZ-Binding motif of the HPV16 E6 oncoprotein. Cancers (Basel) 6(3):1553–
1569. https://doi.org/10.3390/cancers6031553
190. Carvalho J, Paiva A, Cabral Campello MP, Paulo A, Mergny JL, Salgado GF, Queiroz JA,
Cruz C (2019) Aptamer-based targeted delivery of a G-quadruplex ligand in cervical cancer
cells. Sci Rep 9(1):7945. https://doi.org/10.1038/s41598-019-44388-9
191. Carvalho J, Lopes-Nunes J, Lopes AC, Cabral Campello MP, Paulo A, Queiroz JA, Cruz
C (2019) Aptamer-guided acridine derivatives for cervical cancer. Org Biomol Chem
17(11):2992–3002. https://doi.org/10.1039/c9ob00318e
192. Xu G, Yu X, Zhang J, Sheng Y, Liu G, Tao W, Mei L (2016) Robust aptamer-polydopaminefunctionalized M-PLGA-TPGS nanoparticles for targeted delivery of docetaxel and enhanced
cervical cancer therapy. Int J Nanomedicine 11:2953–2965. https://doi.org/10.2147/ijn.S10
3513
193. Jiao L, Ghorani E, Sebire NJ, Seckl MJ (2016) Intraplacental choriocarcinoma: systematic
review and management guidance. Gynecol Oncol 141(3):624–631. https://doi.org/10.1016/
j.ygyno.2016.03.026
194. Dong J, Cao Y, Shen H, Ma Q, Mao S, Li S, Sun J (2018) EGFR aptamer-conjugated liposomepolycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells. Biomed Pharmacother 107:849–859. https://doi.org/10.1016/j.biopha.2018.
08.042
195. Brody H (2015) Colorectal cancer. Nature 521(7551):S1. https://doi.org/10.1038/521S1a
196. Cancer Fact Sheet, World Health Organization. https://www.who.int/en/news-room/fact-she
ets/detail/cancer
197. Cao H, Xu E, Liu H, Wan L, Lai M (2015) Epithelial-mesenchymal transition in colorectal
cancer metastasis: a system review. Pathol Res Pract 211(8):557–569. https://doi.org/10.1016/
j.prp.2015.05.010
198. Martowicz A, Rainer J, Lelong J, Spizzo G, Gastl G, Untergasser G (2013) EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports
hyperplastic growth. Mol Cancer 12:56. https://doi.org/10.1186/1476-4598-12-56
199. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent
EpCam protein expression in human carcinomas. Hum Pathol 35(1):122–128
200. AlShamaileh H, Wang T, Xiang D, Yin W, Tran PH, Barrero RA, Zhang PZ, Li Y, Kong L,
Liu K, Zhou SF, Hou Y, Shigdar S, Duan W (2017) Aptamer-mediated survivin RNAi enables
5-fluorouracil to eliminate colorectal cancer stem cells. Sci Rep 7(1):5898. https://doi.org/10.
1038/s41598-017-05859-z
201. Mashreghi M, Zamani P, Moosavian SA, Jaafari MR (2020) Anti-Epcam Aptamer (Syl3c)functionalized liposome for targeted delivery of doxorubicin: in vitro and in vivo antitumor
H. Jin
184. Wang TH, Chao A, Tsai CL, Chang CL, Chen SH, Lee YS, Chen JK, Lin YJ, Chang PY, Wang
CJ, Chao AS, Chang SD, Chang TC, Lai CH, Wang HS (2010) Stress-induced phosphoprotein
1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. Mol
Cell Proteomics 9(9):1873–1884. https://doi.org/10.1074/mcp.M110.000802
185. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM (2012)
Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical
infection to cancer. Int J Cancer 131(10):2349–2359. https://doi.org/10.1002/ijc.27485
186. Jeon S, Lambert PF (1995) Integration of human papillomavirus type 16 DNA into the
human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical
carcinogenesis. Proc Natl Acad Sci U S A 92(5):1654–1658. https://doi.org/10.1073/pnas.92.
5.1654
187. Leija-Montoya AG, Benítez-Hess ML, Toscano-Garibay JD, Alvarez-Salas LM (2014) Characterization of an RNA aptamer against HPV-16 L1 virus-like particles. Nucl Acid Ther
24(5):344–355. https://doi.org/10.1089/nat.2013.0469
188. Nicol C, Bunka DH, Blair GE, Stonehouse NJ (2011) Effects of single nucleotide changes
on the binding and activity of RNA aptamers to human papillomavirus 16 E7 oncoprotein.
Biochem Biophys Res Commun 405(3):417–421. https://doi.org/10.1016/j.bbrc.2011.01.044
189. Belyaeva TA, Nicol C, Cesur O, Travé G, Blair GE, Stonehouse NJ (2014) An RNA aptamer
targets the PDZ-Binding motif of the HPV16 E6 oncoprotein. Cancers (Basel) 6(3):1553–
1569. https://doi.org/10.3390/cancers6031553
190. Carvalho J, Paiva A, Cabral Campello MP, Paulo A, Mergny JL, Salgado GF, Queiroz JA,
Cruz C (2019) Aptamer-based targeted delivery of a G-quadruplex ligand in cervical cancer
cells. Sci Rep 9(1):7945. https://doi.org/10.1038/s41598-019-44388-9
191. Carvalho J, Lopes-Nunes J, Lopes AC, Cabral Campello MP, Paulo A, Queiroz JA, Cruz
C (2019) Aptamer-guided acridine derivatives for cervical cancer. Org Biomol Chem
17(11):2992–3002. https://doi.org/10.1039/c9ob00318e
192. Xu G, Yu X, Zhang J, Sheng Y, Liu G, Tao W, Mei L (2016) Robust aptamer-polydopaminefunctionalized M-PLGA-TPGS nanoparticles for targeted delivery of docetaxel and enhanced
cervical cancer therapy. Int J Nanomedicine 11:2953–2965. https://doi.org/10.2147/ijn.S10
3513
193. Jiao L, Ghorani E, Sebire NJ, Seckl MJ (2016) Intraplacental choriocarcinoma: systematic
review and management guidance. Gynecol Oncol 141(3):624–631. https://doi.org/10.1016/
j.ygyno.2016.03.026
194. Dong J, Cao Y, Shen H, Ma Q, Mao S, Li S, Sun J (2018) EGFR aptamer-conjugated liposomepolycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells. Biomed Pharmacother 107:849–859. https://doi.org/10.1016/j.biopha.2018.
08.042
195. Brody H (2015) Colorectal cancer. Nature 521(7551):S1. https://doi.org/10.1038/521S1a
196. Cancer Fact Sheet, World Health Organization. https://www.who.int/en/news-room/fact-she
ets/detail/cancer
197. Cao H, Xu E, Liu H, Wan L, Lai M (2015) Epithelial-mesenchymal transition in colorectal
cancer metastasis: a system review. Pathol Res Pract 211(8):557–569. https://doi.org/10.1016/
j.prp.2015.05.010
198. Martowicz A, Rainer J, Lelong J, Spizzo G, Gastl G, Untergasser G (2013) EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports
hyperplastic growth. Mol Cancer 12:56. https://doi.org/10.1186/1476-4598-12-56
199. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent
EpCam protein expression in human carcinomas. Hum Pathol 35(1):122–128
200. AlShamaileh H, Wang T, Xiang D, Yin W, Tran PH, Barrero RA, Zhang PZ, Li Y, Kong L,
Liu K, Zhou SF, Hou Y, Shigdar S, Duan W (2017) Aptamer-mediated survivin RNAi enables
5-fluorouracil to eliminate colorectal cancer stem cells. Sci Rep 7(1):5898. https://doi.org/10.
1038/s41598-017-05859-z
201. Mashreghi M, Zamani P, Moosavian SA, Jaafari MR (2020) Anti-Epcam Aptamer (Syl3c)functionalized liposome for targeted delivery of doxorubicin: in vitro and in vivo antitumor